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Chronic ischemic mitral regurgitation (IMR) remains 
one of the most complex items and unresolved aspects in 
the management of ischemic heart disease. Functional 
IMR is a valve disease, characterised by apparently 
normal leaflets and subvalvular apparatus. It occurs in 
approximately 20% to 25% of patients who suffered 
from an acute myocardial infarction (AMI) and repre-
sents a robust independent risk factor for mortality.1 
Grigioni et al. showed that the presence of functional 
IMR in patients with coronary artery disease is associ-
ated with an excess of mortality rate, independent of 
baseline patient characteristics and degree of LV dys-
function.2 Moreover, in the Grigioni paper, high mortal-
ity rate was found to be directly related to the grade of 
IMR, evaluated by echocardiography using quantitative 
methods and, specifically, the effective regurgitant orifice 
area value (EROA). These authors reported that patients 
who had an AMI and concomitant functional IMR with 
an EROA ≥20 mm² displayed a worse prognosis.2,3
Nowadays, there is general agreement that patients 
with moderate-to-severe or severe chronic IMR should 
undergo mitral valve surgery at the time of coronary 
artery bypass grafting (CABG), while trace-to-mild IMR 
can probably be left untreated. However, the manage-
ment of moderate IMR is still controversial.4–7 Indications 
for the surgical treatment of moderate chronic IMR were 
not highlighted in the AHA/ACC guidelines,8 while a 
Class IIa recommendation to adding restrictive mitral 
valve annuloplasty during CABG was found in the ESC 
guidelines.9 Recently, in the executive summary of the 
ACCF/AHA guidelines for coronary artery bypass graft 
surgery, the authors recommended surgical treatment of 
moderate IMR during CABG (Class IIa).10
Usually, the echocardiographic evaluation of IMR is 
performed by both semi-quantitative and quantitative 
methods. The PISA or the stroke volume methods have 
high sensibility and specificity for the quantification of 
MR degree. Four grades of MR can be identified (Grade 
I = mild, Grade II = moderate, Grade III = moderate-to-
severe, Grade IV = severe). Degenerative MR is considered 
severe when the regurgitant volume (RV) is ≥ 60ml or 
the EROA is ≥ 40mm2. On the other hand, according to 
the work of Grigioni and Lancellotti, functional IMR has 
been defined as severe for lower values of RV (≥30ml) 
and EROA (≥20 mm²).2,3
Although there is wide consensus regarding the 
cut-off value defining the severity of functional IMR, 
considerable controversies have been found in the 
quantification of moderate IMR. So, it is mandatory to 
quantify this lesion well for a better understanding of its 
impact on clinical outcomes.
In the recent literature, though there have been pro-
gressive changes in the definition of moderate IMR, there 
is still confusion among authors regarding the cut-off 
value characterizing moderate IMR.4,5,11,12
So far, a common language for defining the presence 
of moderate IMR has not yet been established. By doing 
so, this could better guide our physicians in clinical 
decision making. Furthermore, we need to avoid what 
happened in the past. Indeed, according to those previ-
ous reports (different grade of MR and different entity 
of the pathology), no robust conclusion can be made 
about the management and the clinical impact of mod-
erate IMR. As in degenerative MR, the quantitative eval-
uation of IMR appears to be the gold standard method. 
Using the conventional colour Doppler flow mapping in 
the left atrium and the measurement of the regurgitant 
jet width to quantify IMR may be subject to errors. In 
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most cases, the regurgitant jet is eccentric due to asym-
metric tenting of the posterior leaflet and the size and 
width of the colour jet may be underestimated. 
Moreover, most of the patients with IMR use diuretic 
therapy that changes heart loading and leads to changes 
in colour regurgitant jet mapping into the left atrium. 
The quantitative method using Doppler measurement 
of stroke volumes or, when feasible, the analysis of the 
flow convergence zone using the PISA method are more 
accurate. It has been shown that the RV and, specifically, 
the EROA are less load-dependent and more reliable. 
Nevertheless, we must keep in mind that IMR is a 
dynamic lesion, depending on the hemodynamic condi-
tions, and its severity may vary over time. The use of 
inotropic agents or diuretics may alter the loading con-
ditions and can substantially modify the real entity of 
IMR. The chronic volume overload in a ventricle that 
has decreased compliance causes an increase in ventric-
ular wall stress and in end-diastolic pressures that lead 
to more LV remodelling and, subsequently, worsening 
MR, creating a vicious circle. Furthermore, the evalua-
tion of mild-to-moderate IMR must be performed, not 
only in resting conditions, but, also, under exercise 
testing.13 This helps us to a better understanding of the 
entity of the lesion and its impact on symptoms, leading 
to exact treatment choice.
In our recent study, we evaluated the impact of mod-
erate IMR (EROA = 10-19 mm²) on the clinical out-
comes of patients undergoing isolated CABG.14 The 
5-year free from all deaths and cardiac-related deaths 
among patients without IMR versus with IMR were, 
respectively, 90.5% ± 1.8% versus 73.7% ± 2.1% 
(p<0.001) and 94.2% ± 1.6% versus 79.5% ± 1.5% 
(p<0.001). Therefore, patients with IMR and EROA = 
10-19 mm² had a worse prognosis and a higher 5-year 
mortality and morbidity compared with those without 
any grade of IMR who underwent isolated CABG.
In our opinion, there is an urgent need to homogenize 
the definition of moderate IMR, with the goal of a better 
understanding of this clinical entity. Two points of view 
may be considered. The first one, a new scaled-grade will 
be used for IMR (Mild: EROA <10 mm², Moderate: 
EROA = 10-19 mm², Severe: EROA ≥20 mm²). The sec-
ond point of view is to keep the existing definitions, 
which are based on physiological measurements (i.e. an 
EROA of 20-40 is moderate and an EROA >40 is severe) 
and recognize, instead, that moderate functional ischae-
mic MR has an adverse prognosis and mitral valve inter-
vention should also be considered in these patients. The 
analogy to this is in the case of tricuspid regurgitation 
(TR) where it is accepted that moderate functional TR in 
the presence of tricuspid annular dilatation is a surgical 
indication. The definition of moderate TR has not been 
changed to severe (as has been suggested for ischaemic 
MR), but, instead, the recommendation is for surgical 
intervention in moderate TR.
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